Information for participants

This section contains the following:


Introduction

The process of obtaining informed consent to take part in a trial (including a choice not to take part) requires steps to be taken to protect an individual’s right to make choices.  These steps include:


Researchers must also attend to the quality of a patient’s understanding as part of this process.  This includes an understanding of:


In obtaining informed consent, the investigator is required to comply with the applicable regulatory requirements, and should adhere to International Conference on Harmonization Guideline for Good Clinical Practice ( ICH GCP ) to the ethical principles that have their origin in the Declaration of Helsinki, and to any local ethical guidelines.  

For most trials it is appropriate to have an information sheet or leaflet summarising key information about the trial.  This information may be verbal, written, or pictorial and should be given to the person when they are approached about the trial.  The information sheet/leaflet should also provide contact details for the trial.  The wording should be comprehensible to participants in terms of both language and style.  Consultation with consumer groups and people who have experienced the clinical condition is advisable.  Before the trial starts, the investigator should receive written approval of any information sheets/leaflets to be provided to potential participants from an independent ethics committee.  

At the end of the trial the investigator should notify participants of trial findings, provide information regarding which group they were assigned to and, if applicable, provide details of how to get the treatment which proved to be effective (see Notifying participants of trial findings).


Back to top


Things to consider when writing a protocol